Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
about
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patientsPre-treatment considerations in childhood hypertension due to chronic kidney diseaseA computerized treatment algorithm trial to optimize mineral metabolism in ESRD.Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs.A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM)Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT studyEffectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT studyAn open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects.Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study.The regulation of parathyroid hormone secretion and synthesis.Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.Cinacalcet: will it play a role in reducing cardiovascular events?Cinacalcet and Clinical Outcomes in Dialysis.Cinacalcet in hyperparathyroidism management after pediatric renal transplantation.Partial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report.Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study.Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols.CKD-MBD KDIGO guidelines: how difficult is reaching the 'target'?Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis.
P2860
Q24187385-948CBA18-0C50-423C-ADC5-2538EAC4C81DQ26777613-CEB49ECB-00C6-45C0-ABAC-346875C4B869Q30421529-C4CBDE62-7AE4-4912-8999-229FF89EF2A6Q33862710-4001C133-A564-4E34-961A-5580034BC9EDQ34362759-794DAAD2-50D9-4B75-A0D5-EDADCEE13E3BQ35026640-7F418529-FE03-43E4-ACB8-EE631D131E84Q35682192-180D8E5F-46D7-48DF-8CF5-F527EA74AF58Q35920190-FD0F4BAE-1811-4C9A-B0EB-6943AD400EBCQ36121519-A70758D7-0A11-47FC-84A9-BB20486FCBE8Q36129859-788CEDD2-19D3-448C-8CE3-C0F47E5BCD89Q36173980-0A7D5240-6194-4C99-86CB-632D0CE72A6AQ36432849-F3213C12-7384-44BD-9097-EEFF9C8DCE46Q36994093-231264C5-024F-4EA3-BA25-7E7F4191EF77Q37310824-D157DF0C-7F75-4727-A76D-4EE5618A82C5Q37638757-9779EB04-3AC3-428A-93B0-3D70641E6386Q37821623-72BA1394-37C5-498C-A2BE-913E43127783Q37891153-74FBB339-4D98-405C-96F5-4A18553C7A1FQ37916534-45D9B2FA-37E5-49BF-A270-F3DFDB0DD20DQ37993874-23032E53-1A22-4F5B-A7E6-5D1E19C6D67EQ38565049-808CB14D-BEA1-466F-873A-D7CDE8C6D826Q42289870-77E750E1-81F3-4203-B690-858690091A17Q42461866-C4E2F2AD-F64B-45BA-9ADF-D6AD56E34E5BQ42683242-68B40F81-9351-4944-9E74-65FF5877B1ECQ44186583-45D30EBB-A2A0-41DF-B25E-75574BE1DB83Q46305757-38E3E736-DB2D-45AA-A98F-B4C8A8108D1AQ50022061-DA990628-04F9-4531-812B-14C2EEB3FE04Q50034239-DF7EF269-4E81-44BB-BA50-62E046E97EF9Q53157310-65A1D2AF-529C-4C46-A6F5-D35E4E5C909C
P2860
Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Combined therapy with cinacalc ...... secondary hyperparathyroidism.
@en
Combined therapy with cinacalc ...... secondary hyperparathyroidism.
@nl
type
label
Combined therapy with cinacalc ...... secondary hyperparathyroidism.
@en
Combined therapy with cinacalc ...... secondary hyperparathyroidism.
@nl
prefLabel
Combined therapy with cinacalc ...... secondary hyperparathyroidism.
@en
Combined therapy with cinacalc ...... secondary hyperparathyroidism.
@nl
P2093
P921
P356
P1476
Combined therapy with cinacalc ...... secondary hyperparathyroidism.
@en
P2093
David A Bushinsky
Eric M Chi
Geoffrey A Block
Glenn M Chertow
Jared Sugihara
Steven Zeig
Stewart A Turner
TARGET Investigators
P304
P356
10.1093/NDT/GFN026
P407
P577
2008-02-29T00:00:00Z